Vijaya Ramachandran Fig S1 D C Supplementary Figures Invasion Apoptosis A Proliferation BxPC3 0 100 200 300 400 500 % of Viable Cells  AGR2(nM) 0 10 100.

Slides:

Advertisements

Similar presentations

Apaf-1 Caspase-9 Cyt c control sulindac control E LY control TRAIL thapsigargin HT-29Chondrocyte control SIN-1 RAW IP: AChE C Supplementary.

Advertisements

Compound 5 Structure hLDHA IC ± µM hLDHB IC ± 0.07 µM Supplementary Figure S1.

Figure S1 b a c Supplement Figure 1. Basic functional characterization of B10G5 antibody. a. B10G5 neutralizing free sMICA in in vitro assay. Various concentration.

WT KO A B Suppl. Fig 1 Supplemental Figure 1. The expression of CYLD in liver. (A) Immunohistochemical analysis of CYLD in liver tissue of adult wildtype.

Supplementary Figures&Legends. Figure1. Subcutaneous xenograft tumor models of the control group.

A U87 non-stem U87 stem-like U251 non-stem U251 stem-like MFI/FOV:TLR9 ** ,000 1,400 MFI/FOV:pSTAT ,200 ***

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.

Figure 1 B D DOX ( μ M) C Cell Proliferation (% Con) MCF-7MCF-7/DOX DOX ( μ M) 0.03% 38.79% 0.15% 0.10% 0.20% 0.05%

CohortTreatment groups DoseMode of administration Number of animals DT01 + OXA + 5-FU sacrificed day 22 Vehicle (NaCl + glucose) 0.9% 5% IP 9 OXA 5-FU.

Supplemental Figure S1 A B MDA-MB-231 MCF-7 BCL-2MDA-MB-231 BCL-2 MCF-7 Bcl-2 Actin Bcl-2 Actin.

Fig. S1 Production of Fc-GITR-L fusion protein Fc fragment Ig  light chain leader sequence signal peptide Transmemberance and intracellular domain Extracellular.

1A 1B 1C 1D Supplementary Fig. 1. Treatment of VEGF-C with the human acute myeloid leukemic cell line,THP-1, induced angiogenesis in vitro. (A and B) Treatment.

Supplementary Methods

supplementary Fig. 1 Anti-HSP70 Ab Anti-SHP2 Ab

Supplementary Figure 1. A B C MP-MRT-AN KP-MRT-NS KP-MRT-RY KP-MRT-YM

Volume 14, Issue 4, Pages (October 2008)

Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Induce Expression of CXCR4 on Human Endothelial Cells Rosalba Salcedo, Ken Wasserman,

Relative FOXM1and Met protein levels (normalized to GAPDH)

A. B. BxPC-3 PANC h h h h h 100 *** * 72 h Cell viability (%) 80 *** *** Cell viability (%) 80 *** *** 60 *** ***

Fig. 4. Effect of FTY720 on brain tumor stem cell (BTSC) invasiveness

Cell Physiol Biochem 2017;44:1867– DOI: /

Volume 18, Issue 12, Pages (December 2016)

Volume 12, Issue 3, Pages (September 2007)

LOXL2 is required for EMT and migration in pancreas cancer

Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases.

Volume 144, Issue 2, Pages (February 2013)

Role of hypoxia-inducible factor-1 alpha in the regulation of plasminogen activator activity in rat knee joint chondrocytes G. Zhu, Y. Tang, X. Liang,

Volume 117, Issue 4, Pages (October 1999)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Stromal Fibroblast–Specific Expression of ADAM-9 Modulates Proliferation and Apoptosis in Melanoma Cells In Vitro and In Vivo Anna N. Abety, Jay W. Fox,

Volume 44, Issue 1, Pages (January 2006)

Elevated expression of CD147 in patients with endometriosis and its role in regulating apoptosis and migration of human endometrial cells Aihong Jin,

Days after cell inoculation Days after cell inoculation

Days after cell inoculation Days after cell inoculation

Volume 141, Issue 4, Pages e2 (October 2011)

Supplementary Figure 2. Effect of IL-32 and siRNA of IL-32 on melanoma, colon and prostate cancer cell growth and apoptosis as well as IL-32 expression.

Figure 2S (Supplementary Data)

Volume 18, Issue 2, Pages (January 2017)

A Hexokinase 2 Modulator for Field-Directed Treatment of Experimental Actinic Keratoses Vered Behar, Hadas Pahima, Adi Kozminsky-Atias, Nir Arbel, Emmanuel.

Relative mRNA expression level (/J3T-1)

Volume 134, Issue 5, Pages (May 2008)

B A D C * * E F Panc-1 cells Figure S1 DNA ladder h

Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice Yongxia Wu, David Bastian, Steven Schutt, Hung Nguyen,

Volume 7, Issue 2, Pages (February 2010)

Ryang Hwa Lee, Nara Yoon, John C. Reneau, Darwin J. Prockop

Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy Shinya Mizuno, Kunio Matsumoto, Toshikazu Nakamura

Volume 21, Issue 5, Pages (May 2013)

Anti-tumor effect of anti-PD-1 antibody against SCC3 tumor

Nehad Abdulgader Shaer Pathophysiology

(apoptotic + necrotic)

Activation of Akt as a Mechanism for Tumor Immune Evasion

Volume 68, Issue 2, Pages (August 2005)

Marta Vilalta, Marjan Rafat, Amato J. Giaccia, Edward E. Graves

Volume 15, Issue 1, Pages (January 2009)

Induction of Angiopoietin-2 gene expression by COX-2: A novel role for COX-2 inhibitors during hepatocarcinogenesis Shinji Tanaka, Jack R. Wands, Shigeki.

Mutant Alanine Position

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Fig. 5. Combination of SAHA and ML produces augmented suppression of cellular proliferation with impaired cell cycle progression, enhanced apoptotic.

Gemcitabine-Incorporated G-Quadruplex Aptamer for Targeted Drug Delivery into Pancreas Cancer Jun Young Park, Ye Lim Cho, Ju Ri Chae, Sung Hwan Moon,

mTORC1 is required to prevent cellular senescence.

Tumors treated with anti-Flk-1 mAb have increased tumor cell apoptosis, reduced tumor cell proliferation, and increased tumor necrosis. s.c. Tumors treated.

Antitumor effects of celastrol in vitro and in vivo.

MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. MEDI4736 shows antitumor activity in xenograft mouse models of human cancer.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

A B HPAF-II CFPAC-1 cells Drug concentration, µM 50

Increased expression of angiogenic factors and inflammatory cytokines in mice exposed to hypoxia. Increased expression of angiogenic factors and inflammatory.

Targeting GAPLINC decreased CD44 expression and tumor growth in vivo.

PDL192 and inhibit the growth of xenograft tumors.

Depletion of murine Dnmt proteins after 5-Aza-CdR treatment.

Bezafibrate increases the number of effector CTLs by enhancing their survival capacity and proliferation. Bezafibrate increases the number of effector.

Presentation transcript:

Vijaya Ramachandran Fig S1 D C Supplementary Figures Invasion Apoptosis A Proliferation BxPC % of Viable Cells  AGR2(nM)  % of Viable Cells  MiaPaCa-2  AGR2(nM) B Migration BxPC3   Migrated Cells per field AGR2(nM)   MiaPaCa-2 Migrated Cells per field AGR2(nM)   BxPC3 Invaded Cells per field AGR2(nM) MiaPaCa-2   Invaded Cells per field AGR2(nM)

Vijaya Ramachandran Lysate+IgG Ab (Mouse) Lysate+AGR2 Ab (Mouse) 25kD 75kD 50kD 35kD CD59 – 30kD 20kD 15kD 10kD Lysate alone Marker B 25kD 75kD 50kD 35kD 100kD 250kD 150kD C4.4A – 50kD Lysate+IgG Ab (Mouse) Lysate+AGR2 Ab (Mouse) Lysate alone Marker A Lysate+IgG Ab (Mouse) Lysate+AGR2 Ab (Mouse) 25kD 75kD 50kD 35kD uPAR – 52kD 20kD 15kD 10kD Lysate alone Marker C Fig S2 WB

Vijaya RamachandranFig S2 25kD 75kD 50kD 35kD 100kD 250kD 150kD UPAR – 52kD 5nM Marker E 10nM 5nM 10nM  -Actin – 42kD SiCon SiUPAR 25kD 75kD 50kD 35kD 100kD 250kD 150kD C4.4A – 50kD F  -Actin – 42kD 5nM Marker 10nM 5nM 10nM SiCon SiC4.4A 25kD 75kD 50kD 35kD 100kD 250kD 150kD CD59 – 30kD D  -Actin – 42kD 5nM Marker 10nM 5nM 10nM SiCon SiCD59 WB

Vijaya Ramachandran C4.4A – 50kD Marker 25kD 75kD 50kD 35kD 100kD 250kD 150kD G. IP Fig S2 Marker BxPC-3 SU86.86 MPanc96 MiaPaCa-2 Panc-1 CFPac-1 AsPC-1 H. RT-PCR Blank C4.4A I. WB Marker BxPC-3 SU86.86 MPanc96 MiaPaCa-2 Panc-1 HPac-1 HPAF-2 CFPac-1 AsPC-1 C4.4A 25kD 75kD 50kD 35kD 100kD 250kD 150kD rProteins +AGR2 Ab rProteins +IgG Ab

BxPC-3 SiCont SiC44ASiCD59 SiUPAR Viable Cells (% SiControl)  A Vijaya Ramachandran Fig S % of apoptotic cells   Gem(1uM) AGR2(100nm) BxPC-3 SiControlSiC4.4A D   Invasion Migration Proliferation Apoptosis  B SiCont SiC44ASiCD59 SiUPAR Migratd Cells (% SiControl)  SiCont SiC44ASiCD59 SiUPAR Migrated Cells (% SiControl + AGR2) + AGR2  SiCont SiC44ASiCD59 SiUPAR Viable Cells (% SiControl + AGR2)  C SiCont SiC44ASiCD59 SiUPAR Invaded Cells (% SiControl)  SiCont SiC44ASiCD59 SiUPAR Invaded Cells (% SiControl + AGR2) Basal + AGR2

Vijaya Ramachandran Fig S4 BxPC-3 AGR  SiControl SiITG-  6 SiITG-  1 SiITG-  4 SiLAM1SiLAM5  Viable Cells (% SiCon) B 

Marker Endo Recomb Commercial Ab Marker Endo Recomb 1A Marker Endo Recomb 1C Marker Endo Recomb 2B Marker Endo Recomb 8 Marker Endo Recomb 9B 10A11A12A 13A14B15B B. C4.4A mAbs Binding: Marker Endo Marker Endo Marker Endo Marker Endo Marker Endo Marker Endo Comm Ab 3A6A9B 10A15B B28B29B30 A. AGR2 mAbs Binding: Vijaya Ramachandran Fig S5

Vijaya Ramachandran Fig S5 C. AGR2 mAbs Apoptosis Assay: D.C4.4A mAbs Apoptosis Assay: E. AGR2 - ELISA Binding Assay: G. Ab Purity: F. C4.4A - ELISA Binding Assay:

Vijaya Ramachandran Fig S6 A. Model 1-AsPc-1-Aggressive Model-Tumor Volume B. Model 2-CaPan-2-Stromal Model-Tumor Volume C. Model 3-CaPan-2-Regression Study-Tumor Volume Group Mice Control IgG Control IgG+Gem Combo IgG Combo IgG+Gem Weeks 7 Tumor Volume (Photons / cm 2 x ) Sacrificed Treated Control Ab AGR2 Ab C4.4A Ab Weeks Tumor Volume (Photons / cm 2 x ) Group Mice No Treatment Treated Individual Mice No Treatment Treated Group Mice Control Ab AGR2 Ab C4.4A Ab Combo Ab Weeks Tumor Volume (Photons / cm 2 x ) Treated Individual Mice Treated Individual Mice Sacrificed Treated